BioAtla BCAB
OTC BCAB
$1.35 -0.15 (-10.00%)
At close: Sep 30, 2026 · 4:00 PM EDT

BioAtla (BCAB) Price to Sales (2020 - 2026)

Updated

BioAtla's (BCAB) Price to Sales stood at 0.81 in Q2 2026, down 99.2% from 105.70 a year earlier.

Analysis

BioAtla (BCAB) Price to Sales (2020 - 2026) Analysis & Trends

For FY2025, BioAtla's Price to Sales came in at 901.19, up 477.4% from FY2024.

  • Across earlier years, Price to Sales came in at 156.08 in FY2024 and 140547.79 in FY2021 (-54.9%).
  • The Q2 2026 figure is the lowest quarterly Price to Sales in data going back to Q4 2020.
  • On a year-over-year basis, Price to Sales rose in 1 of the last four quarters, with growth averaging 57.0%.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 BioAtla 2.25 Mn 2.25 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 0.81
Dec 31, 2025 901.19
Sep 30, 2025 183.86
Jun 30, 2025 105.70
Dec 31, 2024 156.08
Sep 30, 2024 386.76
Sep 30, 2023 16,288.51
Dec 31, 2021 140,547.79
Sep 30, 2021 207,201.24
Jun 30, 2021 171,190.31
Mar 31, 2021 240,529.72
Dec 31, 2020 311,434.00
API Access

BioAtla Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=BCAB&period=max&api_key=YOUR_API_KEY